Payment overview · 2025
General Payments
$1,166.24
74 reported records · 13 companies
Healthcare provider profile · identity verified
David P Buras, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COLLEGE STATION, TX · NPI 1245301373
Verified facts
What the public records show
CMS Open Payments records show David P Buras, MD received $1,166.24 in general payments during 2025 across 74 reported records.
Novo Nordisk Inc accounted for 37.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Synthroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 507 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $437.04 | 37.5% | 30 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $143.85 | 12.3% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $135.91 | 11.7% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $123.41 | 10.6% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $97.05 | 8.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.67 | 4.9% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $55.72 | 4.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.47 | 2.9% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $21.37 | 1.8% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $16.24 | 1.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.66 | 1.3% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $15.16 | 1.3% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.69 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,166.24 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $330.30 | 21 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $249.74 | 15 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $205.08 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $135.91 | 13 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $120.51 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $106.74 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $97.05 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.67 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $55.72 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.03 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.03 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 211 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 261 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 507 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
175 | 46 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
211 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
211 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
261 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
120 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
507 | 97 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1203 | 321 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1003 | 231 |
| Amlodipine Besylate | Amlodipine Besylate | 644 | 169 |
| Alprazolam | Alprazolam | 631 | 143 |
| Ozempic | Semaglutide | 507 | 97 |
| Omeprazole | Omeprazole | 485 | 134 |
| Losartan Potassium | Losartan Potassium | 474 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 392 | 106 |
| Zolpidem Tartrate | Zolpidem Tartrate | 367 | 96 |
| Metformin Hcl | Metformin Hcl | 347 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 318 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 312 | 83 |
| Lisinopril | Lisinopril | 291 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 73 |
| Donepezil Hcl | Donepezil Hcl | 277 | 69 |
| Gabapentin | Gabapentin | 275 | 67 |
| Tramadol Hcl | Tramadol Hcl | 269 | 69 |
| Mounjaro | Tirzepatide | 261 | 37 |
| Simvastatin | Simvastatin | 260 | 69 |
| Citalopram Hbr | Citalopram Hydrobromide | 255 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 255 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 252 | 186 |
| Pravastatin Sodium | Pravastatin Sodium | 251 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 60 |
| Ezetimibe | Ezetimibe | 214 | 55 |
| Methylprednisolone | Methylprednisolone | 213 | 155 |
| Jardiance | Empagliflozin | 211 | 39 |
| Trazodone Hcl | Trazodone Hcl | 202 | 49 |
| Allopurinol | Allopurinol | 199 | 52 |
| Eliquis | Apixaban | 199 | 39 |
| Spironolactone | Spironolactone | 198 | 48 |
| Furosemide | Furosemide | 187 | 53 |
| Synthroid | Levothyroxine Sodium | 175 | 46 |
| Sertraline Hcl | Sertraline Hcl | 168 | 44 |
| Montelukast Sodium | Montelukast Sodium | 156 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 154 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 152 | 40 |
| Carvedilol | Carvedilol | 146 | 31 |
| Potassium Chloride | Potassium Chloride | 143 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 31 |
| Icosapent Ethyl | Icosapent Ethyl | 135 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 54 |
| Alendronate Sodium | Alendronate Sodium | 131 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 37 |
| Trulicity | Dulaglutide | 120 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 119 | 25 |
| Bupropion Xl | Bupropion Hcl | 113 | 23 |
| Memantine Hcl | Memantine Hcl | 112 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 31 |
| Clonazepam | Clonazepam | 108 | 14 |
| Estradiol | Estradiol | 94 | 38 |
| Metformin Hcl Er | Metformin Hcl | 93 | 24 |
| Vascepa | Icosapent Ethyl | 93 | 20 |
| Farxiga | Dapagliflozin Propanediol | 91 | 17 |
| Aripiprazole | Aripiprazole | 88 | 21 |
| Azithromycin | Azithromycin | 86 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 85 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 20 |
| Celecoxib | Celecoxib | 80 | 21 |
| Mirtazapine | Mirtazapine | 80 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 16 |
| Clindamycin Hcl | Clindamycin Hcl | 72 | 59 |
| Famotidine | Famotidine | 72 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 69 | 16 |
| Pregabalin | Pregabalin | 69 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 24 |
| Finasteride | Finasteride | 68 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 45 |
| Atenolol | Atenolol | 65 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 65 | 12 |
| Meloxicam | Meloxicam | 63 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 14 |
| Irbesartan | Irbesartan | 58 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 55 | 11 |
| Risperidone | Risperidone | 55 | suppressed |
| Topiramate | Topiramate | 54 | suppressed |
| Acyclovir | Acyclovir | 53 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 43 |
| Enalapril Maleate | Enalapril Maleate | 52 | suppressed |
| Temazepam | Temazepam | 51 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 50 | 11 |
| Myrbetriq | Mirabegron | 47 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 46 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 36 |
| Carisoprodol | Carisoprodol | 44 | 15 |
| Ramipril | Ramipril | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 11 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 40 | 14 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 38 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 18 |
| Dutasteride | Dutasteride | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 21 |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 34 | suppressed |
| Diazepam | Diazepam | 34 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 14 |
| Levofloxacin | Levofloxacin | 33 | 27 |
| Metronidazole | Metronidazole | 33 | 22 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 15 |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 11 |
| Lorazepam | Lorazepam | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Colchicine | Colchicine | 30 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 29 | suppressed |
| Prednisone | Prednisone | 29 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Kerendia | Finerenone | 25 | suppressed |
| Armour Thyroid | Thyroid,pork | 23 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | 11 |
| Copaxone | Glatiramer Acetate | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Premarin | Estrogens, Conjugated | 22 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Glyburide | Glyburide | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Multaq | Dronedarone Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 11 |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Yuvafem | Estradiol | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Veozah | Fezolinetant | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,166.24 · 74 records | Novo Nordisk Inc | Cologuard Collection Kit, Flector, GEMTESA, JARDIANCE, JATENZO, Kerendia, Korlym, Licart, MOUNJARO, OFEV, OTEZLA, Ozempic, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, Tirosint, UNITHROID, VRAYLAR, Wegovy, XYOSTED, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error